Top-up funding awarded to 76 ERC grantees to bring frontier research closer to market

Top-up funding awarded to 76 ERC grantees to bring frontier research closer to market

Seventy-six top researchers will receive ERC Proof of Concept grants of €150,000 each. This top-up funding is awarded to ERC grantees to explore the innovation potential of their scientific discoveries and bring the results of their frontier research closer to market. This final injection of €11.4 million pushes the total number of ERC Proof of Concept funded projects for 2019 to 200. With the additional money researchers can, for example, investigate business opportunities, establish intellectual property rights or conduct technical validation for their frontier research findings. The recipients of these most recent grants will carry out a wide range of projects. One project based in Italy will develop a safer, tolerable and cheaper treatment alternative for patients with autoimmune conditions such as arthritis. In the UK, a researcher will establish a method to measure if autistic children are getting the intended benefits from the educational programs that are designed to help them. In Ireland a scientist will work to increase the accuracy and lower the cost of optical sensors commonly used in manufacturing, healthcare and the evaluation of water and air quality. Full details of highlighted funded projects This completes the third and final round of the 2019 ERC Proof of Concept grant competition. The overall budget of the 2019 competition was €30 million. Overall last year 498 proposals were evaluated, with an average success rate of 40%. Two hundred grants were awarded to researchers working in 22 countries: Austria 2, Belgium 8, Switzerland 13, Czechia 1, Germany 15, Denmark 3, Greece 2, Spain 16, Finland 8, France 18, Hungary 2, Ireland 6, Israel 10, Italy 20, Luxembourg 1, Netherlands 24, Portugal 4, Romania 2, Sweden 1, Slovenia 1, Turkey 1, UK 34. Related Stories



Also in Industry News

How to decide whether or not to start treatment for prostate cancer?
How to decide whether or not to start treatment for prostate cancer?

0 Comments

How to decide whether or not to start treatment for prostate cancer?

Read More

Analysis of the SARS-CoV-2 proteome via visual tools
Analysis of the SARS-CoV-2 proteome via visual tools

0 Comments

Analysis of the SARS-CoV-2 proteome via visual tools

Read More

$65m investment increases British Patient Capital’s exposure to life sciences and health technology
$65m investment increases British Patient Capital’s exposure to life sciences and health technology

0 Comments

$65m investment increases British Patient Capital’s exposure to life sciences and health technology

Read More